title: Increased expression of insulin-like growth factor-binding protein-3 is implicated in erectile dysfunction in two-kidney one-clip hypertensive rats after propranolol treatment.
abstract: This study aimed to investigate the role of insulin-like growth factor-binding protein-3 (IGFBP-3) in erectile dysfunction (ED) in two-kidney one-clip (2K-1C) hypertensive rats treated with the β-blocking agent propranolol. Adult male Wistar rats were randomly divided into three groups: a normal control group, a hypertensive control group and a propranolol treatment group (n=9). After 4 weeks of propranolol treatment, intracavernous pressure (ICP) responses to electrical stimulation of the cavernous nerves were evaluated. The expression of IGFBP-3 and insulin-like growth factor-1 (IGF-1) mRNA and protein in the rat cavernous tissue were detected by quantitative real-time PCR and Western blot, respectively. The concentration of cyclic guanosine monophosphate (cGMP) in the cavernous tissue was determined by enzyme-linked immunosorbent assay (ELISA). Cavernosal pressure in response to cavernous nerve stimulation was decreased 4 weeks after propranolol treatment (P<0.01, compared to the hypertensive control group). IGFBP-3 mRNA and protein expression was increased in the propranolol treatment group compared to the hypertensive control group (P<0.01), whereas IGF-1 expression was decreased in the propranolol treatment group compared to the hypertensive control group (P<0.01). In addition, cavernous cGMP concentration was decreased in the propranolol treatment group compared to the hypertensive control group (P<0.01). Taken together, these results suggest that the upregulation of IGFBP-3 may play a role in the development of ED in hypertensive rats.
authors.affiliation: Department of Urology, Zhongnan Hospital of Wuhan University, Wuhan 430071, China.
authors.forename: Zhang-Yan
authors.initials: ZY
authors.lastname: Zhou
authors.forename: Zhong-Hua
authors.initials: ZH
authors.lastname: Yang
authors.forename: Xing-Huan
authors.initials: XH
authors.lastname: Wang
authors.forename: Hong
authors.initials: H
authors.lastname: Cao
authors.forename: Dong
authors.initials: D
authors.lastname: Chen
authors.forename: Yong-Zhi
authors.initials: YZ
authors.lastname: Wang
authors.forename: Hai-Hong
authors.initials: HH
authors.lastname: Zhou
authors.forename: Mou
authors.initials: M
authors.lastname: Peng
authors.forename: Quan-Liang
authors.initials: QL
authors.lastname: Liu
authors.forename: Shao-Ping
authors.initials: SP
authors.lastname: Wan
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001483:Base Sequence; D015153:Blotting, Western; D017931:DNA Primers; D004797:Enzyme-Linked Immunosorbent Assay; D007172:Erectile Dysfunction / Q000150:complications / Q000378:metabolism*; D006973:Hypertension / Q000150:complications / Q000188:drug therapy / Q000378:metabolism*; D018972:Insulin-Like Growth Factor Binding Protein 3 / Q000378:metabolism*; D008297:Male; D011433:Propranolol / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D060888:Real-Time Polymerase Chain Reaction
chemical_list: D000959:Antihypertensive Agents; D017931:DNA Primers; D018972:Insulin-Like Growth Factor Binding Protein 3; D011433:Propranolol